Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 69 of 104, showing 5 Applications out of 518 total, starting on record 341, ending on 345

# Protocol No Study Title Investigator(s) & Site(s)

341.

ECCT/18/07/06   Hestia 3
    A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Prof Jessie Nyokabi Githanga
2. Videlis Nduba
3. Janet N Oyieko
4. Bernards Ragama Ogutu
Site(s) in Kenya
1. Gertrude’s Children’s Hospital (Nairobi City county)
2. Chandaria Health Center Clinical Research Clinic (Nairobi City county)
3. Kenya Medical Research Institute (KEMRI) Kisumu (Kisumu county)
4. KEMRI Kombewa Clinical Research Centre (Nairobi City county)
5. Kondele Children\'s Hospital (Kisumu county)
6. Strathmore University Medical Centre (Nairobi City county)
 
View

342.

ECCT/16/07/02   A Randomized Trial of Inflienza Vaccine to Reduce Adverse Vascular Events
    A Randomized Trial of Inflienza Vaccine to Reduce Adverse Vascular Events   
Principal Investigator(s)
1. Mark Loeb
Site(s) in Kenya
The Aga Khan University Hospital
 
View

343.

ECCT/22/10/03   ISSC
    A randomized, double-blind, placebo-controlled trial to assess the safety, pharmacokinetics, and efficacy of escalating doses of oral ivermectin in scabies infected children weighing 5 to less than 15 kilograms in Kenya   
Principal Investigator(s)
1. Eunice Akinyi Ouma
Site(s) in Kenya
Jaramogi Oginga Odinga Teaching and Referral Hospital
 
View

344.

ECCT/21/07/06   GBT132_Inclacumab-Ps 3 Trial
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises.   
Principal Investigator(s)
1. Fredrick Asirwa Chite
2. Videlis N Nduba
3. Bernhards Ragama Ogutu
Site(s) in Kenya
1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Strathmore University Medical Centre (Nairobi City county)
 
View

345.

ECCT/21/12/07   GBT 132- Inclacumab Phase 3
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises.   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Videlis N Nduba
3. Fredrick Asirwa Chite
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
3. KEMRI/CRDR (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
 
View